How Windgap is reducing environmental impact through innovation, partnerships, and a proactive approach.

How Windgap Medical’s lyophilized autoinjector platforms cut CO2 Emissions and Costs

Discover how automating, accelerating, and simplifying complex drug delivery can save time, resources, energy—and the planet.

Find out how lyophilization, long-acting injectables, and sequential delivery can substantially reduce waste and environmental impact.

Pharmaceutical companies that want to ‘move the needle’ on sustainability efforts can take a more proactive approach to reduce their footprints. Here’s why.

Windgap Medical offers drug delivery devices that simplify, auto-mate, and accelerate the administration of complex injectables.

Brent Buchine, Miriam Silton, Jameson Woods and Andrew Ryan explore how the combination of gas power and a side-by-side cartridge configuration increases the working viscosity range for the mixing and delivery of complex injectable formulations.

Windgap Medical Appoints Max Meehan as Director of Corporate Development and Strategy

The autoinjector platform company known for its wet-dry drug delivery technology expands the leadership team.

The autoinjector platform company known for its wet-dry drug delivery technology expands the leadership team.

The autoinjector platform company known for its wet-dry drug delivery technology deepens its leadership bench.

Brent Buchine considers a faster path to market for automated and easy-to-use reconstitution devices through simplification of the delivery systems.

Co-Founder Brent Buchine discusses the need for automated, easy-to-use reconstitution devices, especially in lyophilised medications, and introduces Windgap Medical’s technology platforms, which rise to the challenge.

Windgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced today that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital.

Under the grant, researchers from the University's Center for Drug Design, College of Pharmacy, and Massachusetts-based pharmaceutical company Windgap Medical are collaborating to design an autoinjector.

Windgap Medical, Inc. announced today that it has a strategic partnership with ALK-Abelló, A/S ("ALK") to commercialize the company's epinephrine autoinjector (EAI) for the treatment of anaphylactic shock.

Windgap Medical, Inc. announced today that it has finalized a deal to enable a strategic investment from Molex Ventures, LLC, a subsidiary of Koch Industries ("Molex Ventures").

Announces next round of Life Sciences Accelerator Loan Program